PET-CT Beyond FDG A Quick Guide to Image Interpretation

Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET-CT, there are some settings in which other radiopharmaceuticals offer advantages. Such non-FDG tracers are now gaining widespread acceptance not only in research but also in clini...

Full description

Bibliographic Details
Main Authors: Fanti, Stefano, Farsad, Mohsen (Author), Mansi, Luigi (Author)
Format: eBook
Language:English
Published: Berlin, Heidelberg Springer Berlin Heidelberg 2010, 2010
Edition:1st ed. 2010
Subjects:
Online Access:
Collection: Springer eBooks 2005- - Collection details see MPG.ReNa
LEADER 02570nmm a2200313 u 4500
001 EB000381725
003 EBX01000000000000000234777
005 00000000000000.0
007 cr|||||||||||||||||||||
008 130626 ||| eng
020 |a 9783540939092 
100 1 |a Fanti, Stefano 
245 0 0 |a PET-CT Beyond FDG  |h Elektronische Ressource  |b A Quick Guide to Image Interpretation  |c by Stefano Fanti, Mohsen Farsad, Luigi Mansi 
250 |a 1st ed. 2010 
260 |a Berlin, Heidelberg  |b Springer Berlin Heidelberg  |c 2010, 2010 
300 |a X, 243 p  |b online resource 
505 0 |a Importance of Radiotracers Other than FDG in Oncology -- Considerations About PET Isotopes -- Choline PET-CT -- Methionine PET-CT -- Fluoride PET-CT -- Tyrosine PET-CT -- Somatostatin Receptor PET-CT -- Acetate PET-CT -- Thymidine PET-CT -- Dopa PET-CT -- Imaging of Hypoxia with PET-CT -- Angiogenesis PET Using Radiolabeled RGD Peptides -- Hormonal Receptors PET-CT -- HTP PET-CT. 
653 |a Nuclear Medicine 
653 |a Radiology 
653 |a Nuclear medicine 
653 |a Oncology 
700 1 |a Farsad, Mohsen  |e [author] 
700 1 |a Mansi, Luigi  |e [author] 
041 0 7 |a eng  |2 ISO 639-2 
989 |b Springer  |a Springer eBooks 2005- 
028 5 0 |a 10.1007/978-3-540-93909-2 
856 4 0 |u https://doi.org/10.1007/978-3-540-93909-2?nosfx=y  |x Verlag  |3 Volltext 
082 0 |a 616.0757 
520 |a Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET-CT, there are some settings in which other radiopharmaceuticals offer advantages. Such non-FDG tracers are now gaining widespread acceptance not only in research but also in clinical practice, with the acquisition of promising results in the management of various cancers. This atlas, including about 500 high-quality images, is a user-friendly guide to PET-CT imaging beyond FDG. A wide range of tracers is covered, such as 18F- and 11C-choline, 11C-methionine, 18F-ethyl-L-tyrosine, 68Ga-DOTA-NOC, 11C-acetate, 11C-thymidine, and 18F-DOPA. Throughout, the emphasis is on image interpretation, with guidance on the recognition of normal, benign, and malignant uptake and clear instruction on learning points and pitfalls. This book is a companion to the editors’ recently published Atlas of PET-CT, which focuses exclusively on the use of FDG. It is designed to serve as a reference text for both nuclear physicians and radiologists, and will also be of great benefit to radiographers, technologists, and nuclear medicine and radiology residents